¾«¶«Ó°Òµ

¾«¶«Ó°Òµ. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that its Taiwan subsidiary ¾«¶«Ó°ÒµTaiwan Inc. has entered into an asset sale/purchase agreement to divest its Tainan Plant to Taiwanese pharmaceutical company Bora Corporation (Headquarters: Taipei, Chairman & CEO: Bobby Sheng, “Bora”).

Since commencing operations in 1974, the Tainan Plant has performed its role as a production base that serves emerging countries, particularly in Asia. In recent years, however, the environment surrounding the pharmaceutical industry has been undergoing rapid changes. In order to better and more accurately identify and respond to diversifying customer needs in the pharmaceutical industry, ¾«¶«Ó°Òµunderwent a transformation in October 2012 that saw its existing production structure, which was based on manufacturing sites managed by region, shift to a globally integrated, unit-based structure organized by product family. Based on a review conducted under the new production structure, which evaluated Eisai's global supply chain strategy in terms of efficiency and productivity, ¾«¶«Ó°Òµand ¾«¶«Ó°ÒµTaiwan Inc. have decided to divest the Tainan Plant to Bora. ¾«¶«Ó°ÒµTaiwan Inc. will now move ahead with the procedures necessary to complete the divestment based on local laws and regulations, with the divestment expected to be completed by September 2013.

¾«¶«Ó°Òµremains committed to providing high-quality medicines at affordable prices and delivering products that create customer joy, regardless of the challenges posed to the pharmaceutical manufacturing sector by a rapidly changing and increasingly globalized market environment. In doing so, ¾«¶«Ó°Òµwill continue to make contributions to increase the benefits provided to patients and their families worldwide.

[Please refer to the following notes for further information on the Tainan Plant and Bora.]